نتایج جستجو برای: nonsmall cell lung cancer nsclc

تعداد نتایج: 2482650  

2001
C. Gessner U. Liebers H. Kuhn P. Stiehl C. Witt J. Schauer G. Wolff

BAX and p16 are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. C. Gessner, U. Liebers, H. Kuhn, P. Stiehl, C. Witt J. Schauer, G. Wolff. #ERS Journals Ltd 2002. ABSTRACT: Clinical studies suggest prognostic relevance of p16 in nonsmall cell lung cancer (NSCLC) while conflicting results for p53 have been published. However, the importance of the a...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2009
Giulia Bertolini Luca Roz Paola Perego Monica Tortoreto Enrico Fontanella Laura Gatti Graziella Pratesi Alessandra Fabbri Francesca Andriani Stella Tinelli Elena Roz Roberto Caserini Salvatore Lo Vullo Tiziana Camerini Luigi Mariani Domenico Delia Elisa Calabrò Ugo Pastorino Gabriella Sozzi

The identification of lung tumor-initiating cells and associated markers may be useful for optimization of therapeutic approaches and for predictive and prognostic information in lung cancer patients. CD133, a surface glycoprotein linked to organ-specific stem cells, was described as a marker of cancer-initiating cells in different tumor types. Here, we report that a CD133+, epithelial-specific...

2015
Ting Zhang Ge Cui Yun-Liang Yao Yue Guo Qi-Chun Wang Xi-Ning Li Wen-Ming Feng

BACKGROUND Protein arginine methyltransferases 1 (PRMT1) is over-expressed in a variety of cancers, including lung cancer, and is correlated with a poor prognosis of tumor development. This study aimed to investigate the role of PRMT1 in nonsmall cell lung cancer (NSCLC) migration in vitro. METHODS In this study, PRMT1 expression in the NSCLC cell line A549 was silenced using lentiviral vecto...

Journal: :European respiratory review : an official journal of the European Respiratory Society 2015
Sandra Wallerek Jens Benn Sørensen

Biomarkers may be useful when deciding which nonsmall cell lung cancer (NSCLC) patients may benefit from adjuvant chemotherapy following complete resection and which chemotherapeutic agents may be used preferably in individual patients in order to maximise survival. A literature search covering the period from 2003 to May, 2014 was conducted using PubMed and the following search terms: "non-sma...

Journal: :The European respiratory journal 2013
Rudolf M Huber Martin Reck Michael Thomas

Stage III nonsmall cell lung cancer (NSCLC) encompasses a heterogeneous group of patients, some of whom may be candidates for potentially curative surgery, although for the majority surgery is not an option. Recommended therapy for patients with unresectable stage III disease is concurrent treatment with chemotherapy and thoracic radiotherapy, although even with this dual modality therapy survi...

2017
Andri W. Orrason Martin I. Sigurdsson Kristjan Baldvinsson Hunbogi Thorsteinsson Steinn Jonsson Tomas Gudbjartsson

We studied the rate of incidental detection of lung carcinomas and its effect on long-term survival in a nationwide cohort of patients operated for nonsmall cell lung cancer (NSCLC). All patients operated for NSCLC in Iceland during 1991–2010 were included. Demographic and clinicopathological features were compared in patients diagnosed incidentally using chest radiography or computed tomograph...

Journal: :The European respiratory journal 2012
T Berghmans F Pasleau M Paesmans Y Bonduelle J Cadranel I Cs Toth C Garcia V Giner S Holbrechts J J Lafitte J Lecomte I Louviaux E Markiewicz A P Meert M Richez M Roelandts A Scherpereel Ch Tulippe P Van Houtte P Van Schil C Wachters V Westeel J P Sculier

The present systematic review was performed under the auspices of the European Lung Cancer Working Party (ELCWP) in order to determine the role of early intermediate criteria (surrogate markers), instead of survival, in determining treatment efficacy in patients with lung cancer. Initially, the level of evidence for the use of overall survival to evaluate treatment efficacy was reviewed. Nine q...

2017
Tongpeng Xu Hao Wu Shidai Jin Huang Min Zhihong Zhang Yongqian Shu Wei Wen Renhua Guo

RATIONALE Tyrosine kinase inhibitors (TKIs) are known to have greater efficacy in epidermal growth factor receptor (EGFR) mutation nonsmall cell lung cancer (NSCLC). However, about 10% of EGFR wild-type (wt) patients respond to TKIs. PATIENT CONCERNS Several strategies to increase the efficacy of TKIs in wt NSCLC are the subjects of ongoing investigations. One of them is combining EGFR TKI wi...

Journal: :The European respiratory journal 2014
Lucia Kim Ming Sound Tsao

In the era of personalised cancer therapy, the demand for molecular profiling of the patient's tumour is steadily increasing. In advanced nonsmall cell lung cancer (NSCLC) patients, testing for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements has become an essential component of clinical practice to select patients who are most likely to...

2014
Yao Fong Yin-Chieh Lin Chang-Yi Wu Hui-Min David Wang Li-Li Lin Han Lin Chou Yen-Ni Teng Shyng-Shiou Yuan Chien-Chih Chiu

Sirtuins, NAD(+)-dependent deacetylases, could target both histones and nonhistone proteins in mammalian cells. Sirt1 is the major sirtuin and has been shown to involve various cellular processes, including antiapoptosis, cellular senescence. Sirt1 was reported to be overexpressed in many cancers, including lung cancer. Sirtinol, a specific inhibitor of Sirt1, has been shown to induce apoptosis...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید